Fig. 2 | Cellular & Molecular Immunology

Fig. 2

From: The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation

Fig. 2

The antitumor activity of APG-2575 is CD8+ T-cell driven, and APG-2575 induces antitumor CD8+ T-cell immunity by regulating macrophages. A‒C Tumor volume comparison in APG-2575-treated LLC tumor-bearing C57BL/6 mice with or without depletion of CD3+, CD4+ or CD8+ T cells. D UMAP plot of human tumor-infiltrating CD45+ cells from the two groups merged and analyzed by scRNA-seq. E UMAP plots with annotated clusters of intratumoral immune cells from the control and APG-2575 groups. F The proportions of different immune cells in the control and APG-2575 groups. G Tumor volume comparison in APG-2575-treated LLC tumor-bearing C57BL/6 mice in the absence or presence of PLX3397. H‒J Flow cytometric analysis of CD8+, CD8 + GZMB+ and CD8+ TNF-α + T cells in C57BL/6 mouse xenograft tumors. K, L Kaplan‒Meier analysis of OS in patients in TCGA cohorts based on the M1 and M2 macrophage infiltration levels. M, O Representative multiplex immunofluorescence images demonstrating the CD11B + CD86+ (M1 macrophages), CD11B+CD206+ (M2 macrophages) and pan-CK (cancer cells) expression signatures in samples from responders and nonresponders. N, P Kaplan‒Meier analysis of PFS in patients based on M1 and M2 macrophage infiltration levels detected in tumors

Back to article page